Is BHC or CRMD more profitable?

CorMedix has a net margin of 40.49% compared to Bausch Health Cos' net margin of -10.12%. CorMedix's return on equity of 40.52% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -10.12% -561.95% 6.31% CorMedix 40.49% 40.52% 20.61%

Does the media prefer BHC or CRMD?

In the previous week, Bausch Health Cos had 1 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Bausch Health Cos and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Bausch Health Cos' score of 0.45 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PBH or CRMD?

In the previous week, CorMedix had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 4 mentions for CorMedix and 2 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat CorMedix's score of 0.78 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prestige Consumer Healthcare 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLYS or CRMD?

In the previous week, Mineralys Therapeutics had 7 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Mineralys Therapeutics' score of 0.38 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, TRLV or CRMD?

CorMedix has lower revenue, but higher earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.18B 1.77 -$116.38M N/A N/A CorMedix $311.71M 1.82 $163.05M $2.14 3.40

Does the media prefer TRLV or CRMD?

In the previous week, Trulieve Cannabis had 5 more articles in the media than CorMedix. MarketBeat recorded 9 mentions for Trulieve Cannabis and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Trulieve Cannabis' score of 0.29 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CRMD or URGN?

CorMedix has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 1.81 $163.05M $2.14 3.38 Urogen Pharma $109.79M 15.78 -$153.49M -$1.98 N/A

Does the media favor CRMD or URGN?

In the previous week, CorMedix had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Urogen Pharma. CorMedix's average media sentiment score of 0.78 beat Urogen Pharma's score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CorMedix (CRMD) Competitors

$7.32 +0.04 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$7.34 +0.02 (+0.27%)

As of 07:30 PM Eastern

Compare

CRMD vs. BHC, PBH, MLYS, TRLV, and URGN

Should you buy CorMedix stock or one of its competitors? CorMedix's main competitors and comparable companies include Bausch Health Cos (BHC), Prestige Consumer Healthcare (PBH), Mineralys Therapeutics (MLYS), Trulieve Cannabis (TRLV), and Urogen Pharma (URGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CorMedix compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Bausch Health Cos had 1 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Bausch Health Cos and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Bausch Health Cos' score of 0.45 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 30.19%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 107.61%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CorMedix has lower revenue, but higher earnings than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.22	$157M	-$2.96	N/A
CorMedix	$311.71M	1.81	$163.05M	$2.14	3.38

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CorMedix has a net margin of 40.49% compared to Bausch Health Cos' net margin of -10.12%. CorMedix's return on equity of 40.52% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
CorMedix	40.49%	40.52%	20.61%

Bausch Health Cos has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Summary

CorMedix beats Bausch Health Cos on 12 of the 17 factors compared between the two stocks.

How does CorMedix compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

CorMedix has a net margin of 40.49% compared to Prestige Consumer Healthcare's net margin of 15.57%. CorMedix's return on equity of 40.52% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
CorMedix	40.49%	40.52%	20.61%

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, CorMedix had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 4 mentions for CorMedix and 2 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat CorMedix's score of 0.78 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prestige Consumer Healthcare presently has a consensus price target of $67.67, indicating a potential upside of 42.23%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 106.04%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Prestige Consumer Healthcare has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33
CorMedix	$311.71M	1.82	$163.05M	$2.14	3.40

Prestige Consumer Healthcare has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

CorMedix beats Prestige Consumer Healthcare on 9 of the 17 factors compared between the two stocks.

How does CorMedix compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

CorMedix has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
CorMedix	$311.71M	1.82	$163.05M	$2.14	3.40

CorMedix has a net margin of 40.49% compared to Mineralys Therapeutics' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
CorMedix	40.49%	40.52%	20.61%

In the previous week, Mineralys Therapeutics had 7 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Mineralys Therapeutics' score of 0.38 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mineralys Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Mineralys Therapeutics currently has a consensus target price of $48.80, suggesting a potential upside of 120.91%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 106.04%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

CorMedix beats Mineralys Therapeutics on 11 of the 15 factors compared between the two stocks.

How does CorMedix compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

CorMedix has a net margin of 40.49% compared to Trulieve Cannabis' net margin of -41.55%. CorMedix's return on equity of 40.52% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
CorMedix	40.49%	40.52%	20.61%

Trulieve Cannabis presently has a consensus target price of $15.00, indicating a potential upside of 38.54%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 106.04%. Given CorMedix's stronger consensus rating and higher possible upside, analysts plainly believe CorMedix is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Trulieve Cannabis had 5 more articles in the media than CorMedix. MarketBeat recorded 9 mentions for Trulieve Cannabis and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.78 beat Trulieve Cannabis' score of 0.29 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has lower revenue, but higher earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.18B	1.77	-$116.38M	N/A	N/A
CorMedix	$311.71M	1.82	$163.05M	$2.14	3.40

34.2% of CorMedix shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CorMedix beats Trulieve Cannabis on 10 of the 13 factors compared between the two stocks.

How does CorMedix compare to Urogen Pharma?

CorMedix (NASDAQ:CRMD) and Urogen Pharma (NASDAQ:URGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 107.61%. Urogen Pharma has a consensus price target of $52.38, suggesting a potential upside of 47.79%. Given CorMedix's stronger consensus rating and higher probable upside, equities research analysts plainly believe CorMedix is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

CorMedix has a net margin of 40.49% compared to Urogen Pharma's net margin of -51.73%. CorMedix's return on equity of 40.52% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Urogen Pharma	-51.73%	N/A	-43.79%

CorMedix has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

In the previous week, CorMedix had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Urogen Pharma. CorMedix's average media sentiment score of 0.78 beat Urogen Pharma's score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.2% of CorMedix shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CorMedix has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.81	$163.05M	$2.14	3.38
Urogen Pharma	$109.79M	15.78	-$153.49M	-$1.98	N/A

Summary

CorMedix beats Urogen Pharma on 11 of the 16 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$570.52M	$12.24B	$7.14B	$13.21B
Dividend Yield	N/A	2.65%	2.53%	16.47%
P/E Ratio	3.42	802.38	275.15	25.94
Price / Sales	1.83	747.53	566.78	83.59
Price / Cash	3.56	86.04	77.41	52.81
Price / Book	1.42	10.66	10.80	6.27
Net Income	$163.05M	$2.83B	$3.50B	$382.13M
7 Day Performance	-1.35%	-1.65%	-2.02%	-1.39%
1 Month Performance	-10.51%	-7.68%	-7.54%	-5.62%
1 Year Performance	-35.05%	-6.28%	3.31%	-1.54%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.5544 of 5 stars	$7.32 +0.5%	$15.00 +104.9%	-34.4%	$570.52M	$311.71M	3.42	191
BHC Bausch Health Cos	3.0445 of 5 stars	$5.91 +1.8%	$8.00 +35.5%	-3.8%	$2.17B	$10.27B	N/A	20,300	Analyst Forecast Options Volume
PBH Prestige Consumer Healthcare	3.6751 of 5 stars	$45.56 +0.7%	$67.67 +48.5%	-24.3%	$2.14B	$1.09B	12.76	890	Positive News
MLYS Mineralys Therapeutics	2.8825 of 5 stars	$23.30 -1.4%	$48.80 +109.4%	-41.3%	$2.09B	N/A	N/A	76
TRLV Trulieve Cannabis	3.0919 of 5 stars	$10.61 -1.1%	$15.00 +41.4%	N/A	$2.06B	$1.18B	N/A	5,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. BHC, PBH, MLYS, TRLV, and URGN

How does CorMedix compare to Bausch Health Cos?

Summary

How does CorMedix compare to Prestige Consumer Healthcare?

Summary

How does CorMedix compare to Mineralys Therapeutics?

Summary

How does CorMedix compare to Trulieve Cannabis?

Summary

How does CorMedix compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. BHC, PBH, MLYS, TRLV, and URGN

How does CorMedix compare to Bausch Health Cos?

Does the media prefer BHC or CRMD?

Do analysts prefer BHC or CRMD?

Which has stronger valuation & earnings, BHC or CRMD?

Do insiders and institutionals hold more shares of BHC or CRMD?

Is BHC or CRMD more profitable?

Which has more volatility and risk, BHC or CRMD?

Summary

How does CorMedix compare to Prestige Consumer Healthcare?

Is PBH or CRMD more profitable?

Do institutionals & insiders have more ownership in PBH or CRMD?

Does the media refer more to PBH or CRMD?

Do analysts rate PBH or CRMD?

Which has better earnings & valuation, PBH or CRMD?

Which has more risk and volatility, PBH or CRMD?

Summary

How does CorMedix compare to Mineralys Therapeutics?

Which has preferable earnings & valuation, MLYS or CRMD?

Is MLYS or CRMD more profitable?

Does the media refer more to MLYS or CRMD?

Do insiders & institutionals have more ownership in MLYS or CRMD?

Which has more volatility & risk, MLYS or CRMD?

Do analysts rate MLYS or CRMD?

Summary

How does CorMedix compare to Trulieve Cannabis?

Is TRLV or CRMD more profitable?

Do analysts recommend TRLV or CRMD?

Does the media prefer TRLV or CRMD?

Which has stronger valuation & earnings, TRLV or CRMD?

Do institutionals & insiders believe in TRLV or CRMD?

Summary

How does CorMedix compare to Urogen Pharma?

Do analysts recommend CRMD or URGN?

Is CRMD or URGN more profitable?

Which has more volatility & risk, CRMD or URGN?

Does the media favor CRMD or URGN?

Do insiders and institutionals hold more shares of CRMD or URGN?

Which has stronger earnings and valuation, CRMD or URGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools